5 Comments

Interesting stock. This one even held up in the bear market of 2022.

Expand full comment

Yes, it is quite impressive.

Expand full comment

Great company bad investement at this price

Expand full comment

So the big questo i clients

Small pharma needs angel investors, usualy coing from private equty.

The money can ran out way quiker than what it looks like to fund new drug development.

The moat in this case goes away.

It is a risky busness and should be treated as such

Expand full comment

Good point. Medpace can be more cyclical in that manner than other more stable quality companies.

Expand full comment